Ultragenyx (RARE) Reports FDA Removal of Clinical Hold on Study

Published on September 28, 2021

Ultragenyx (RARE) and GeneTx Biotherapeutics to start dosing in the phase I/II study on GTX-102 for treating pediatric patients with Angelman syndrome...

Continue reading on website
Other news

Can Analog Devices (ADI) Run Higher on Rising Earnings Estimates?

September 28, 2021
Analog Devices (ADI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Announcing FlexTal + Entrepreneur 2021 Workforce Report

September 28, 2021
The workforce holds the power as companies rush to make decisions for the new normal, a report by FlexTal and Entrepreneur Media finds.